Dianthus Therapeutics, Inc. Common Stock (DNTH)

Price$80.51

Value ScoreF

Growth ScoreF

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)75.14%

Price vs S&P 500 (4W)-7.14%

VGM Score35.03

Market Capitalization$4.40B

All Metrics

Book Value / Share (Quarterly)$22.01

P/TBV (Annual)1.61x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-2.39

Price vs S&P 500 (YTD)87.21%

Net Profit Margin (TTM)-12998.50%

EPS (TTM)$-4.14

10-Day Avg Trading Volume0.72M

EPS Excl Extra (TTM)$-4.14

EPS (Annual)$-4.20

ROI (Annual)-32.90%

Cash / Share (Quarterly)$20.36

Revenue Growth QoQ (YoY)-60.19%

ROA (Last FY)-30.58%

Revenue Growth TTM (YoY)-79.52%

EBITD / Share (TTM)$-4.59

ROE (5Y Avg)-39.22%

Operating Margin (TTM)-14318.04%

Cash Flow / Share (Annual)$-2.99

P/B Ratio3.66x

P/B Ratio (Quarterly)3.80x

Net Income / Employee (Annual)$-1,764,500

EV / Revenue (TTM)2824.48x

Net Interest Coverage (TTM)-57.94x

ROA (TTM)-25.91%

EPS Incl Extra (Annual)$-4.20

Current Ratio (Annual)13.32x

Quick Ratio (Quarterly)29.06x

3-Month Avg Trading Volume0.88M

52-Week Price Return333.55%

Revenue / Employee (TTM)$14,500

Tangible BV / Share (Quarterly)$12.04

P/S Ratio (Annual)2161.68x

Asset Turnover (Annual)0.00x

52-Week High$96.50

EPS Excl Extra (Annual)$-4.20

CapEx CAGR (5Y)-11.84%

Tangible BV CAGR (5Y)16.06%

26-Week Price Return83.06%

Quick Ratio (Annual)13.16x

13-Week Price Return31.06%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)29.25x

Enterprise Value$3.77B

Asset Turnover (TTM)0.00x

Book Value / Share Growth (5Y)3.60%

Revenue / Employee (Annual)$22,100

Pretax Margin (Annual)-7973.33%

Cash / Share (Annual)$9.35

3-Month Return Std Dev65.09%

Net Income / Employee (TTM)$-1,887,600

ROE (Last FY)-32.90%

EPS Basic Excl Extra (Annual)$-4.20

Receivables Turnover (TTM)1.20x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-4.14

ROI (TTM)-27.30%

P/S Ratio (TTM)3294.29x

Revenue / Share (Annual)$0.05

Tangible BV / Share (Annual)$27.96

Price vs S&P 500 (52W)309.18%

Year-to-Date Return95.37%

5-Day Price Return-9.99%

EPS Normalized (Annual)$-4.20

ROA (5Y Avg)-33.44%

Net Profit Margin (Annual)-7973.33%

Month-to-Date Return-13.44%

Cash Flow / Share (TTM)$-14.53

EBITD / Share (Annual)$-4.60

Operating Margin (Annual)-8739.34%

ROI (5Y Avg)-39.22%

EPS Basic Excl Extra (TTM)$-4.14

P/TBV (Quarterly)0.96x

P/B Ratio (Annual)3.58x

Pretax Margin (TTM)-12998.50%

Book Value / Share (Annual)$11.42

Price vs S&P 500 (13W)22.80%

Beta1.77x

Revenue / Share (TTM)$0.03

ROE (TTM)-27.30%

52-Week Low$16.64

vGradeF

gGradeF

mGradeB

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.85est. -1.09

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.38

4.41

4.43

4.41

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
DNTHDianthus Therapeutics, Inc. Common Stock	F	F	B	$80.51
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Dianthus Therapeutics is a clinical-stage biotechnology company developing next-generation monoclonal antibody therapies targeting complement for severe autoimmune and inflammatory diseases. The company's lead candidate, DNTH103, is a subcutaneous C1s inhibitor designed to offer improved selectivity and potency over existing complement therapies. The team brings substantial biotechnology and pharmaceutical expertise to advance its pipeline.